Ireland’s Health Service Executive (HSE) has agreed to fund a drug for Friedreich's ataxia after Biogen, the pharmaceutical company, offered a significantly reduced price. The decision follows recent negotiations resulting in a “substantially improved financial offer” from Biogen. While funding has been approved, the HSE has cautioned that the drug’s efficacy is “limited.” This means the benefits for patients may be modest, despite the significant access improvement. The move will provide treatment options for individuals living with this rare, debilitating genetic condition. The HSE’s decision balances the need to manage healthcare budgets with providing access to treatments, even with acknowledged limitations. Further details regarding access criteria and implementation are expected to be released soon.